Abbott (ABT) Stock Rated Buy on Strong Diabetes Trial Results

Abbott Laboratories (NYSE:ABT) ranks among the best most active stocks to buy right now. Following encouraging results from Abbott Laboratories (NYSE:ABT)’s FreeDM trial, Benchmark reiterated a Buy rating and $145 price target for the company’s shares on March 13. In comparison to individuals using whole blood glucose meters with fingerstick blood samples, the trial demonstrated that patients with Type 2 diabetes on basal insulin therapy who employed FreeStyle Libre continuous glucose monitoring technology achieved better glucose results.

The findings from the UK trial were supported by a second interventional trial from Italy delivered at the same conference. Both results emphasize the need for expanded insurance coverage of continuous glucose monitoring in European nations where Libre has not been officially covered.

Although no decision is expected very soon, the CMS is thinking about expanding compensation in the US. According to Benchmark, as one of the top providers of continuous glucose monitoring, Abbott Laboratories (NYSE:ABT) is well-positioned to profit from this development.

Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.